Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aradigm Corp (ARDM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,240
  • Shares Outstanding, K 15,200
  • Annual Sales, $ 14,470 K
  • Annual Income, $ -10,710 K
  • 36-Month Beta 0.58
  • Price/Sales 1.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +384,330.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.10 +9.09%
on 09/25/18
1.95 -38.46%
on 10/03/18
-0.01 (-0.83%)
since 09/18/18
3-Month
1.10 +9.09%
on 09/25/18
1.95 -38.46%
on 10/03/18
-0.26 (-17.81%)
since 07/18/18
52-Week
1.03 +16.50%
on 03/02/18
7.35 -83.67%
on 12/29/17
-4.25 (-77.98%)
since 10/18/17

Most Recent Stories

More News
Consolidated Research: 2018 Summary Expectations for Community Health, Aradigm, Avnet, Sanchez Energy, Black Stone Minerals, and Navient -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Community Health Systems, Inc....

NAVI : 12.44 (-0.32%)
CYH : 2.94 (+1.73%)
ARDM : 1.20 (-1.64%)
SN : 2.22 (+0.45%)
BSM : 17.35 (-1.03%)
AVT : 41.31 (-1.17%)
Aradigm: 2Q Earnings Snapshot

HAYWARD, Calif. (AP) _ Aradigm Corp. (ARDM) on Tuesday reported a second-quarter loss of $3.8 million, after reporting a profit in the same period a year earlier.

ARDM : 1.20 (-1.64%)
Aradigm Announces Second Quarter 2018 Financial Results

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2018.

ARDM : 1.20 (-1.64%)
Factors of Influence in 2018, Key Indicators and Opportunity within Community Health, Monotype Imaging, Cardlytics, Sanchez Energy, First Horizon National, and Aradigm -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Community Health Systems, Inc....

CDLX : 20.44 (-1.16%)
CYH : 2.94 (+1.73%)
ARDM : 1.20 (-1.64%)
SN : 2.22 (+0.45%)
TYPE : 18.80 (-2.34%)
FHN : 15.74 (-1.13%)
New Research Coverage Highlights ProPetro Holding, Aradigm, Ocean Power Technologies, Icahn Enterprises, Granite Point Mortgage Trust, and PBF Logistics LP -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ProPetro Holding Corp. (NYSE:PUMP),...

GPMT : 18.54 (+0.05%)
PBFX : 22.51 (+1.99%)
ARDM : 1.20 (-1.64%)
OPTT : 0.52 (-8.77%)
IEP : 69.92 (+0.36%)
PUMP : 17.74 (+0.91%)
Aradigm: 1Q Earnings Snapshot

HAYWARD, Calif. (AP) _ Aradigm Corp. (ARDM) on Tuesday reported a loss of $4.8 million in its first quarter.

ARDM : 1.20 (-1.64%)
Aradigm Announces First Quarter 2018 Financial Results

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2018.

ARDM : 1.20 (-1.64%)
New Research Coverage Highlights Aradigm, Ultra Petroleum, TRI Pointe Group, Finisar, Tesla, and The Progressive -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aradigm Corporation (NASDAQ:ARDM),...

UPL : 1.42 (+0.71%)
TSLA : 268.49 (+1.74%)
ARDM : 1.20 (-1.64%)
FNSR : 17.84 (+1.42%)
PGR : 70.64 (-1.62%)
TPH : 11.21 (-0.36%)
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Stock Monitor: Bio-Path Holdings Post Earnings Reporting

ARDM : 1.20 (-1.64%)
BPTH : 0.55 (+1.85%)
Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA)...

ARDM : 1.20 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ARDM with:

Business Summary

Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via...

See More

Key Turning Points

2nd Resistance Point 1.25
1st Resistance Point 1.23
Last Price 1.20
1st Support Level 1.19
2nd Support Level 1.17

See More

52-Week High 7.35
Fibonacci 61.8% 4.94
Fibonacci 50% 4.19
Fibonacci 38.2% 3.44
Last Price 1.20
52-Week Low 1.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar